CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its ...
CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...
CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital ...
Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...
ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
Cathie Wood’s ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The investment manager made a notable purchase in gene-editing company CRISPR ...
They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results